FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2992951617> ?p ?o ?g. }

• W2992951617 endingPage "60" @default.
• W2992951617 startingPage "60" @default.
• W2992951617 abstract "Importance Malignant pleural effusion (MPE) is challenging to manage. Talc pleurodesis is a common and effective treatment. There are no reliable data, however, regarding the optimal method for talc delivery, leading to differences in practice and recommendations. Objective To test the hypothesis that administration of talc poudrage during thoracoscopy with local anesthesia is more effective than talc slurry delivered via chest tube in successfully inducing pleurodesis. Design, Setting, and Participants Open-label, randomized clinical trial conducted at 17 UK hospitals. A total of 330 participants were enrolled from August 2012 to April 2018 and followed up until October 2018. Patients were eligible if they were older than 18 years, had a confirmed diagnosis of MPE, and could undergo thoracoscopy with local anesthesia. Patients were excluded if they required a thoracoscopy for diagnostic purposes or had evidence of nonexpandable lung. Interventions Patients randomized to the talc poudrage group (n = 166) received 4 g of talc poudrage during thoracoscopy while under moderate sedation, while patients randomized to the control group (n = 164) underwent bedside chest tube insertion with local anesthesia followed by administration of 4 g of sterile talc slurry. Main Outcomes and Measures The primary outcome was pleurodesis failure up to 90 days after randomization. Secondary outcomes included pleurodesis failure at 30 and 180 days; time to pleurodesis failure; number of nights spent in the hospital over 90 days; patient-reported thoracic pain and dyspnea at 7, 30, 90, and 180 days; health-related quality of life at 30, 90, and 180 days; all-cause mortality; and percentage of opacification on chest radiograph at drain removal and at 30, 90, and 180 days. Results Among 330 patients who were randomized (mean age, 68 years; 181 [55%] women), 320 (97%) were included in the primary outcome analysis. At 90 days, the pleurodesis failure rate was 36 of 161 patients (22%) in the talc poudrage group and 38 of 159 (24%) in the talc slurry group (adjusted odds ratio, 0.91 [95% CI, 0.54-1.55];P = .74; difference, –1.8% [95% CI, –10.7% to 7.2%]). No statistically significant differences were noted in any of the 24 prespecified secondary outcomes. Conclusions and Relevance Among patients with malignant pleural effusion, thoracoscopic talc poudrage, compared with talc slurry delivered via chest tube, resulted in no significant difference in the rate of pleurodesis failure at 90 days. However, the study may have been underpowered to detect small but potentially important differences. Trial Registration ISRCTN Identifier:ISRCTN47845793" @default.
• W2992951617 created "2019-12-13" @default.
• W2992951617 creator A5002724561 @default.
• W2992951617 creator A5003094422 @default.
• W2992951617 creator A5005898198 @default.
• W2992951617 creator A5010081088 @default.
• W2992951617 creator A5015120901 @default.
• W2992951617 creator A5018641575 @default.
• W2992951617 creator A5019605192 @default.
• W2992951617 creator A5019819865 @default.
• W2992951617 creator A5023957322 @default.
• W2992951617 creator A5026183673 @default.
• W2992951617 creator A5030468996 @default.
• W2992951617 creator A5033612364 @default.
• W2992951617 creator A5035054812 @default.
• W2992951617 creator A5036060035 @default.
• W2992951617 creator A5036511466 @default.
• W2992951617 creator A5036990987 @default.
• W2992951617 creator A5037760064 @default.
• W2992951617 creator A5044919811 @default.
• W2992951617 creator A5046185271 @default.
• W2992951617 creator A5048009571 @default.
• W2992951617 creator A5048078917 @default.
• W2992951617 creator A5049329206 @default.
• W2992951617 creator A5053182763 @default.
• W2992951617 creator A5056052687 @default.
• W2992951617 creator A5057031525 @default.
• W2992951617 creator A5059272486 @default.
• W2992951617 creator A5061110223 @default.
• W2992951617 creator A5065487754 @default.
• W2992951617 creator A5067874881 @default.
• W2992951617 creator A5069348015 @default.
• W2992951617 creator A5075329762 @default.
• W2992951617 creator A5075650113 @default.
• W2992951617 creator A5080031942 @default.
• W2992951617 creator A5080049157 @default.
• W2992951617 creator A5081347639 @default.
• W2992951617 creator A5081633297 @default.
• W2992951617 creator A5083237255 @default.
• W2992951617 creator A5085607695 @default.
• W2992951617 creator A5086761550 @default.
• W2992951617 creator A5087411288 @default.
• W2992951617 creator A5089390865 @default.
• W2992951617 creator A5089801695 @default.
• W2992951617 creator A5090913135 @default.
• W2992951617 date "2020-01-07" @default.
• W2992951617 modified "2023-10-10" @default.
• W2992951617 title "Effect of Thoracoscopic Talc Poudrage vs Talc Slurry via Chest Tube on Pleurodesis Failure Rate Among Patients With Malignant Pleural Effusions" @default.
• W2992951617 cites W1975166857 @default.
• W2992951617 cites W1983872259 @default.
• W2992951617 cites W1990166011 @default.
• W2992951617 cites W1998187979 @default.
• W2992951617 cites W2013564592 @default.
• W2992951617 cites W2049150240 @default.
• W2992951617 cites W2061410297 @default.
• W2992951617 cites W2065174445 @default.
• W2992951617 cites W2066589487 @default.
• W2992951617 cites W2088170617 @default.
• W2992951617 cites W2092052931 @default.
• W2992951617 cites W2094866935 @default.
• W2992951617 cites W2100837942 @default.
• W2992951617 cites W2113719548 @default.
• W2992951617 cites W2118051530 @default.
• W2992951617 cites W2122588058 @default.
• W2992951617 cites W2131593307 @default.
• W2992951617 cites W2133581405 @default.
• W2992951617 cites W2136669583 @default.
• W2992951617 cites W2147481343 @default.
• W2992951617 cites W2157149369 @default.
• W2992951617 cites W2168841935 @default.
• W2992951617 cites W2170829864 @default.
• W2992951617 cites W2559297711 @default.
• W2992951617 cites W2770388669 @default.
• W2992951617 cites W2795716722 @default.
• W2992951617 cites W2808492717 @default.
• W2992951617 cites W2884284882 @default.
• W2992951617 cites W2884606331 @default.
• W2992951617 cites W2891136910 @default.
• W2992951617 cites W2894749894 @default.
• W2992951617 cites W2936340413 @default.
• W2992951617 doi "https://doi.org/10.1001/jama.2019.19997" @default.
• W2992951617 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6990658" @default.
• W2992951617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31804680" @default.
• W2992951617 hasPublicationYear "2020" @default.
• W2992951617 type Work @default.
• W2992951617 sameAs 2992951617 @default.
• W2992951617 citedByCount "59" @default.
• W2992951617 countsByYear W29929516172018 @default.
• W2992951617 countsByYear W29929516172020 @default.
• W2992951617 countsByYear W29929516172021 @default.
• W2992951617 countsByYear W29929516172022 @default.
• W2992951617 countsByYear W29929516172023 @default.
• W2992951617 crossrefType "journal-article" @default.
• W2992951617 hasAuthorship W2992951617A5002724561 @default.
• W2992951617 hasAuthorship W2992951617A5003094422 @default.
• W2992951617 hasAuthorship W2992951617A5005898198 @default.
• W2992951617 hasAuthorship W2992951617A5010081088 @default.
• W2992951617 hasAuthorship W2992951617A5015120901 @default.

• next